RecruitingNot Applicable

Effect of Attentional Therapy on Post-traumatic Stress Disorder

France140 participantsStarted 2024-02-02

Plain-language summary

Post-traumatic stress disorder (PTSD) is associated with an attentional bias towards negative stimuli, which is supposed to contribute to the development and the maintenance of the disorder. We recently showed using eye-tracking evidenced two types of AB towards negative stimuli: a "physiological AB" found both in healthy and individual with PTSD, characterized by a stronger initial attentional engagement towards negative stimuli compared to neutral stimuli, as revealed by longer first fixation duration dwell time on negative pictures than on neutral pictures; a "pathological bias" observed only in individuals with PTSD and characterized by an heightened sustained attention towards negative stimuli once detected, which further increases with prolonged exposure. The present study aimed at assessing the effectiveness of an eye-tracking assisted attentional bias reduction therapy, targeting specifically the pathological bias on the reduction of PTSD symptoms

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Understanding and able to express themselves in French * Giving informed consent, by dating and signing the study participation form * Having health insurance coverage * Normal or corrected to normal vision and hearing * DSM-5 PTSD criteria, assessed using the CAPS and PCL-5 Exclusion Criteria: * Minors or adults under guardianship, under judicial protection, persons deprived of liberty * Pregnant or breastfeeding women * Refusal to participate after being clearly and fairly informed about the study * Sensory, visual or auditory incapacity to participate in the study * Personal history of neurological disorder or current neurological disorder * Use of drugs other than tobacco and alcohol * Alcohol use on the day of experimentation * Personal history of psychiatric disorders or current psychiatric disorders other than anxiety, depressive, or trauma and stress disorders assessed at clinical interview and with MINI * Personal history of multiple trauma in childhood * Psychotropic medication treatment not stabilized over the past 4 weeks * MOCA \< 26 * Contraindication to prolonged exposure therapy

What they're measuring

PTSD symptomatology assessed using the Clinician-Administered PTSD Scale (CAPS) score.

Timeframe: Before and after ACTo or ACT treatment: at day 1 and 1 month after inclusion

Trial details

NCT IDNCT05331534

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-02-02

Contact for this trial

Guillaume VAIVA, MD,PhD

0320445962 guillaume.vaiva@chru-lille.fr